RxDoctor Payments Data

Bindu Dey, MD

Internal Medicine · Beacon Falls, CTNPI 1629013503

Payments from drug & device makers

$2,979in general payments, 2019–2025

Across 28 payments — averaging $106.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$838
  • Welch Allyn$838
  • Tosoh Bioscience, Inc.$679
  • GSK$299
  • Novo Nordisk$283
  • Merck$23
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$62521%
  • Gifts$67923%
  • Other$1,67556%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Baxter Healthcare1$838
Welch Allyn1$838
Tosoh Bioscience, Inc.1$679
GSK17$299
Novo Nordisk6$283
Merck1$23
AbbVie1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,979 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$144,561
Medicare patients
232
Services billed
3,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$47,088
JardianceEmpagliflozin20$23,063
JanuviaSitagliptin Phosphate22$19,725
OzempicSemaglutide16$15,012
XareltoRivaroxaban15$14,197
SymbicortBudesonide/Formoterol Fumarate31$7,384
Combivent RespimatIpratropium/Albuterol Sulfate12$5,774
Levothyroxine Sodium304$3,138
SynthroidLevothyroxine Sodium49$3,097
Atorvastatin Calcium315$2,496
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,248
Wixela InhubFluticasone Propion/Salmeterol16$1,730
Omeprazole105$1,603
Lisinopril161$1,324
Amlodipine Besylate207$1,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$23$19,72522 claims
Novo NordiskOzempic$283$15,01216 claims
AbbVieSynthroid$20$3,09749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Beacon Falls

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →